Genome-wide identification of possible methylation markers chemosensitive to targeted regimens in colorectal cancers

摘要: Few efficient methylation markers of chemosensitivity have been discovered. The genome-wide analysis is needed to identify chemosensitive candidates targeted therapy. This study describes a two-step process select genes. A screening genes was performed using Beadarray and an in vitro assay 119 colorectal cancers (CRCs). Ten candidate identified during the initial were verified by biological utility assessment cell viability assays transfected CRC cells. Five related sensitivity bevacizumab regimens (RASSF1, MMP25, KCNQ1, ESR1, GALR2) or cetuximab (SCL18A2, GPX7, NID2, IGFBP3, ALX4) chosen first step. revealed that GALR2-overexpressing HCT116 cells significantly more than control (P = 0.022 0.019 for with FOLFIRI FOLFOX, respectively), concurrently on caspase-3 activity assay. GPX7- ALX4-overexpressed RKO less viable compared (GPX7: P = 0.027 each FOLFOX; ALX4: P = 0.049 0.003 but not prominent GPX7-overexpressed Two novel genes, GALR2 ALX4, as regimens, respectively. As our did include clinical association study, two should be validated large cohorts, hopefully predicting responsive patients regimens.